Phase I (2000-06)

in page functions

Gavi's first five-years focused on getting funds to countries quickly to extend the reach and quality of immunisation programmes

In Gavi's first six years, the Vaccine Alliance concentrated on two primary areas:

  1. supply of new and underused vaccines;
  2. strengthening vaccine delivery systems.

From 2000-06, Gavi's new and underused vaccine support (NVS) focused on three underused vaccines: hepatitis B (hepB), Haemophilus influenzae type b (Hib) and yellow fever.

Support was provided in the form of five-year grants with the expectation that countries would increase their national contribution, leading to eventual financial sustainability.

Delivery systems were improved through Gavi's injection safety support (INS) initiatives. As most infections result from the re-use of equipment, Gavi enabled the supply of disposable auto-disable (AD) syringes for all vaccines to all countries. In addition to minimising infection risk, this helped to drive down the price of AD syringes and increased vaccine demand.

Incentives to immunise more children were given through performance-based funding known as immunisation services support (ISS) with countries receiving extra money per additional child immunised.

Gavi catalyses new injection safety standards

In Gavi’s first 10 years, 58 countries successfully applied for injection safety support. All but two continued to use auto-disposable syringes even after Gavi's support stopped.


Learn more... 

Uganda INS 2009 AD syringes box

41 million

Since 2007, countries have immunised 41 million children with a second dose of measles or measles-rubella vaccine with Gavi support. Gavi-funded campaigns with these two vaccines have helped vaccinate another 328 million children in countries at high risk of outbreaks.

WHO/UNICEF and Gavi, 2017

More facts...

close icon

modal window here